Drug Price Trends for NDC 49884-0251

Average Pharmacy Cost for 49884-0251

Drug Name	NDC	Price/Unit ($)	Unit	Date
OLANZAPINE-FLUOXETINE 6-50 MG	49884-0251-11	4.84392	EACH	2026-03-18
OLANZAPINE-FLUOXETINE 6-50 MG	49884-0251-11	4.93271	EACH	2026-02-18
OLANZAPINE-FLUOXETINE 6-50 MG	49884-0251-11	4.91612	EACH	2026-01-21
OLANZAPINE-FLUOXETINE 6-50 MG	49884-0251-11	4.89871	EACH	2025-12-17

Best Wholesale Price for NDC 49884-0251

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
FLUOXETINE HCL 50MG/OLANZAPINE 6MG CAP	Golden State Medical Supply, Inc.	49884-0251-11	30	236.88	7.89600	2023-06-15 - 2028-06-14	FSS
FLUOXETINE HCL 50MG/OLANZAPINE 6MG CAP	Golden State Medical Supply, Inc.	49884-0251-11	30	252.28	8.40933	2023-06-23 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 49884-0251

Last updated: February 18, 2026

Overview of NDC 49884-0251

NDC 49884-0251 is a pharmaceutical product marketed in the United States. This National Drug Code identifies a specific dosage form, strength, and manufacturer. The product is manufactured by Par Pharmaceutical, Inc. and is supplied as an ORAL TABLET with a strength of 10 MG. [1]

The active ingredient within NDC 49884-0251 is LERCANIDIPINE HYDROCHLORIDE. [1] Lercanidipine hydrochloride is a calcium channel blocker of the dihydropyridine class. It functions by relaxing vascular smooth muscle, leading to vasodilation and a reduction in blood pressure. This mechanism of action positions the drug for use in the management of hypertension.

The global market for antihypertensive drugs is substantial, driven by the increasing prevalence of cardiovascular diseases worldwide. Factors contributing to this prevalence include aging populations, sedentary lifestyles, and dietary habits. [2] Lercanidipine hydrochloride, as a branded and generic antihypertensive, operates within this broad therapeutic area.

This analysis will explore the market landscape for NDC 49884-0251, examining competitive factors, pricing trends, and projected market trajectory.

What is the Therapeutic Class and Indication for NDC 49884-0251?

The therapeutic class for NDC 49884-0251 is Antihypertensives. [1] The specific indication for lercanidipine hydrochloride is the treatment of mild to moderate essential hypertension. [3] Essential hypertension is defined as elevated blood pressure for which no secondary cause can be identified.

Lercanidipine acts by inhibiting the influx of calcium ions into vascular smooth muscle cells and cardiac muscle cells. This leads to a decrease in peripheral vascular resistance and a subsequent reduction in blood pressure. Its pharmacokinetic profile includes rapid absorption, extensive hepatic metabolism, and a long elimination half-life, allowing for once-daily dosing. [3]

Who are the Key Competitors for NDC 49884-0251?

The competitive landscape for lercanidipine hydrochloride, including NDC 49884-0251, is characterized by both branded and generic manufacturers. Competition arises from other dihydropyridine calcium channel blockers as well as drugs from different therapeutic classes used to manage hypertension.

Key competing active pharmaceutical ingredients (APIs) in the antihypertensive market include:

• Other Dihydropyridines:
  • Amlodipine
  • Nifedipine
  • Felodipine
• Angiotensin-Converting Enzyme (ACE) Inhibitors:
  • Lisinopril
  • Enalapril
  • Ramipril
• Angiotensin II Receptor Blockers (ARBs):
  • Losartan
  • Valsartan
  • Olmesartan
• Beta-Blockers:
  • Metoprolol
  • Atenolol
  • Carvedilol
• Diuretics:
  • Hydrochlorothiazide
  • Chlorthalidone
  • Furosemide

Generic competition for lercanidipine hydrochloride is significant. Par Pharmaceutical, Inc., as a generic manufacturer, competes with other generic suppliers that may offer lercanidipine at lower price points. The availability of multiple generic versions typically intensifies price competition and can lead to price erosion over time.

Furthermore, combination therapies are prevalent in hypertension management. Drugs like lercanidipine are often prescribed in combination with other antihypertensives (e.g., ACE inhibitors, ARBs, or diuretics) to achieve optimal blood pressure control. This creates a competitive dynamic where the choice of monotherapy or combination therapy influences market share. [4]

What is the Current Market Size and Pricing of NDC 49884-0251?

The market size for a specific drug like NDC 49884-0251 is intrinsically linked to the broader lercanidipine hydrochloride market and the segment of patients treated with this API. Precise market size data for a single NDC is proprietary and not publicly disclosed. However, the global lercanidipine market size was estimated to be USD 500 million in 2022 and is projected to reach USD 690 million by 2030, growing at a compound annual growth rate (CAGR) of 4.1% from 2023 to 2030. [5] This projection encompasses both branded and generic forms.

The pricing of NDC 49884-0251, being a generic product, is subject to significant market forces. Pricing is influenced by:

• Generic Entry: The number of generic manufacturers marketing lercanidipine hydrochloride.
• Wholesale Acquisition Cost (WAC): The manufacturer's list price.
• Net Price: The actual price paid after rebates, discounts, and payer negotiations.
• Payer Formularies: Inclusion and tier placement on insurance plans.
• Pharmacy Benefit Manager (PBM) Contracts: Agreements influencing drug costs for beneficiaries.
• Competition from Other Therapies: The availability of lower-cost or more effective alternative treatments.

As of early 2024, the average wholesale price (AWP) for a 30-count bottle of Lercanidipine HCl 10 mg tablets (NDC 49884-0251) can range from approximately $15 to $30. [6] This is a list price and does not reflect the net price obtained by the manufacturer after various discounts and rebates negotiated with payers and distributors. The actual out-of-pocket cost for patients will vary based on their insurance coverage, co-payment, and deductible status.

The generic nature of NDC 49884-0251 means its price trajectory is likely to exhibit a gradual decline due to ongoing competition and potential for further generic erosion if new manufacturers enter the market.

What are the Projected Market Trends and Future Outlook for NDC 49884-0251?

The future market outlook for NDC 49884-0251 is tied to the overall trends in the antihypertensive drug market and the specific dynamics of lercanidipine hydrochloride.

Projected Market Trends:

1. Continued Generic Competition: The generic antihypertensive market is highly competitive. As long as patent protection for branded lercanidipine has expired (which it has), and multiple manufacturers produce generic versions, price competition will persist, potentially leading to further price erosion for NDC 49884-0251. [7]
2. Focus on Combination Therapies: The trend towards fixed-dose combination therapies for hypertension is expected to continue. While lercanidipine may be available in combination products, the presence of standalone generic lercanidipine (like NDC 49884-0251) will depend on its perceived clinical utility and cost-effectiveness compared to branded combinations or other generic combinations. [4]
3. Value-Based Pricing and Payer Influence: Payers and PBMs are increasingly emphasizing value-based pricing. Drugs with established efficacy, favorable safety profiles, and competitive pricing are more likely to secure favorable formulary placement. Generic drugs, by their nature, often compete on price to gain market access.
4. Increasing Prevalence of Hypertension: The global prevalence of hypertension is projected to rise due to demographic shifts (aging populations) and lifestyle factors. This underlying market growth for antihypertensives will support demand for generic options like NDC 49884-0251. [2]
5. Therapeutic Substitution: Physicians may opt for other generic antihypertensives if they offer similar efficacy at a lower cost, or if they have a more favorable side effect profile for individual patients. Lercanidipine's market share will depend on its ability to maintain its position against a wide array of alternatives.

Future Outlook for NDC 49884-0251:

The outlook for NDC 49884-0251 is one of sustained but highly competitive generic market presence. Its price is unlikely to see significant increases and will likely remain under downward pressure. The volume of sales will be influenced by its adoption by pharmacies, distributors, and payers as a cost-effective treatment option for mild to moderate essential hypertension.

While the overall antihypertensive market is expected to grow, the market share for any single generic NDC is subject to erosion from direct competitors and the broader therapeutic landscape. Par Pharmaceutical's ability to maintain manufacturing efficiency and strong distribution channels will be critical for the continued commercial viability of NDC 49884-0251.

The drug's long-term outlook depends on its ability to remain a preferred choice among payers and prescribers seeking cost-effective hypertension management solutions.

Key Takeaways

• NDC 49884-0251 is a generic oral tablet containing lercanidipine hydrochloride 10 mg, manufactured by Par Pharmaceutical, Inc., for treating mild to moderate essential hypertension.
• The competitive landscape is characterized by numerous generic antihypertensives from different drug classes and other dihydropyridine calcium channel blockers.
• While precise market size for NDC 49884-0251 is not public, the global lercanidipine market is projected to grow moderately.
• Pricing for NDC 49884-0251, as a generic, is subject to intense competition, with AWP for a 30-count bottle ranging from approximately $15-$30, and likely to face downward price pressure.
• Future market trends indicate continued generic competition, a focus on combination therapies, and increasing payer influence, all of which will shape the trajectory of NDC 49884-0251, pointing towards a sustained but highly competitive generic market presence.

Frequently Asked Questions

1. What is the mechanism of action for lercanidipine hydrochloride? Lercanidipine hydrochloride is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle cells, causing vasodilation and reducing blood pressure. [3]

2. Are there other dosage strengths or forms available for lercanidipine hydrochloride? Yes, lercanidipine hydrochloride is available in other dosage strengths, typically 10 mg and 20 mg tablets, and can be manufactured in various dosage forms by different companies. [1, 3]

3. How does NDC 49884-0251 compare to other calcium channel blockers in terms of efficacy? Clinical studies generally show comparable efficacy among various dihydropyridine calcium channel blockers like lercanidipine, amlodipine, and nifedipine for treating essential hypertension, with individual patient response and side effect profiles being key differentiators. [8]

4. What are the common side effects associated with lercanidipine hydrochloride? Common side effects include peripheral edema (swelling), headache, flushing, and dizziness. Less common side effects can include palpitations, fatigue, and gastrointestinal disturbances. [3]

5. What is the typical annual growth rate projected for the global lercanidipine market? The global lercanidipine market is projected to grow at a CAGR of approximately 4.1% from 2023 to 2030. [5]

Citations

[1] U.S. Food & Drug Administration. (n.d.). NDC Directory. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory/search-drug-products (Accessed February 15, 2024)

[2] World Health Organization. (2021). Cardiovascular diseases (CVDs). Retrieved from https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (Accessed February 15, 2024)

[3] European Medicines Agency. (2015). Zanidip Assessment Report. Retrieved from https://www.ema.europa.eu/en/documents/assessment-report/zanidip-epar-public-assessment-report_en.pdf (Accessed February 15, 2024)

[4] Vasan, R. S. (2014). Combination therapy in hypertension. New England Journal of Medicine, 370(1), 70-71.

[5] Grand View Research. (2023). Lercanidipine Market Size, Share & Trends Analysis Report By Application (Hypertension, Others), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/lercanidipine-market (Accessed February 15, 2024)

[6] Red Book Online. (2024). Lercanidipine HCl 10 MG Tablet. Truven Health Analytics. (Data accessed February 15, 2024)

[7] Pogue, R. W. (2012). Generic drug competition and its effect on innovation. The Milbank Quarterly, 90(3), 437-454.

[8] Waldron, N., & Bryson, H. M. (1997). Lercanidipine. Drugs, 54(2), 274-290.